FGF-21 fusion proteins
The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
09.06.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome. |
---|---|
Bibliography: | Application Number: EP20090150627 |